UK regulator approves second Alzheimer’s drug in months but government won’t pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup